KIN17 functions in DNA damage repair and chemosensitivity by modulating RAD51 in hepatocellular carcinoma-Reference-Cited by-同舟云学术

KIN17 functions in DNA damage repair and chemosensitivity by modulating RAD51 in hepatocellular carcinoma

Published:2024-06-27 Issue:5 Volume:37 Page:1489-1504
ISSN:1749-0774
Container-title:Human Cell
language:en
Short-container-title:Human Cell

Author:

Huang Xueran,Dai Zichang,Zeng Biyun,Xiao Xiangyan,Zahid Kashif Rafiq,Lin Xiaocong,Liu Tiancai,Zeng Tao^ORCID

Funder

Basic and Applied Basic Research Foundation of Guangdong Province

Medical Science and Technology Foundation of Guangdong Province

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13577-024-01096-5.pdf

Reference51 articles.

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

2. Yang Y, Xiong L, Li M, Jiang P, Wang J, Li C. Advances in radiotherapy and immunity in hepatocellular carcinoma. J Transl Med. 2023;21(1):526.

3. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, et al. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 11 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19(4):394–402.

4. Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221–32.

5. Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.